Global Infliximab and Biosimilar Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
According to our (Global Info Research) latest study, the global Infliximab and Biosimilar market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
Infliximab (trade names Remicade among others) is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-?) and is used to treat autoimmune diseases.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the Infliximab and Biosimilar industry chain, the market status of Crohn's Disease (Infliximab, Infliximab-dyyb), Pediatric Crohn's Disease (Infliximab, Infliximab-dyyb), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Infliximab and Biosimilar.
Regionally, the report analyzes the Infliximab and Biosimilar markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Infliximab and Biosimilar market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Infliximab and Biosimilar market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Infliximab and Biosimilar industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Infliximab, Infliximab-dyyb).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Infliximab and Biosimilar market.
Regional Analysis: The report involves examining the Infliximab and Biosimilar market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Infliximab and Biosimilar market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Infliximab and Biosimilar:
Company Analysis: Report covers individual Infliximab and Biosimilar manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Infliximab and Biosimilar This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Crohn's Disease, Pediatric Crohn's Disease).
Technology Analysis: Report covers specific technologies relevant to Infliximab and Biosimilar. It assesses the current state, advancements, and potential future developments in Infliximab and Biosimilar areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Infliximab and Biosimilar market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Infliximab and Biosimilar market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Chapter 1, to describe Infliximab and Biosimilar product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Infliximab and Biosimilar, with price, sales, revenue and global market share of Infliximab and Biosimilar from 2019 to 2024.
Chapter 3, the Infliximab and Biosimilar competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Infliximab and Biosimilar breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Infliximab and Biosimilar market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Infliximab and Biosimilar.
Chapter 14 and 15, to describe Infliximab and Biosimilar sales channel, distributors, customers, research findings and conclusion.
Infliximab (trade names Remicade among others) is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-?) and is used to treat autoimmune diseases.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the Infliximab and Biosimilar industry chain, the market status of Crohn's Disease (Infliximab, Infliximab-dyyb), Pediatric Crohn's Disease (Infliximab, Infliximab-dyyb), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Infliximab and Biosimilar.
Regionally, the report analyzes the Infliximab and Biosimilar markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Infliximab and Biosimilar market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Infliximab and Biosimilar market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Infliximab and Biosimilar industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Infliximab, Infliximab-dyyb).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Infliximab and Biosimilar market.
Regional Analysis: The report involves examining the Infliximab and Biosimilar market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Infliximab and Biosimilar market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Infliximab and Biosimilar:
Company Analysis: Report covers individual Infliximab and Biosimilar manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Infliximab and Biosimilar This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Crohn's Disease, Pediatric Crohn's Disease).
Technology Analysis: Report covers specific technologies relevant to Infliximab and Biosimilar. It assesses the current state, advancements, and potential future developments in Infliximab and Biosimilar areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Infliximab and Biosimilar market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Infliximab and Biosimilar market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
- Infliximab
- Infliximab-dyyb
- Infliximab-abda
- Crohn's Disease
- Pediatric Crohn's Disease
- Ulcerative Colitis
- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Psoriatic Arthritis
- Plaque Psoriasis
- Janssen Biotech
- Merck and Co.
- Pfizer
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Infliximab and Biosimilar product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Infliximab and Biosimilar, with price, sales, revenue and global market share of Infliximab and Biosimilar from 2019 to 2024.
Chapter 3, the Infliximab and Biosimilar competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Infliximab and Biosimilar breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Infliximab and Biosimilar market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Infliximab and Biosimilar.
Chapter 14 and 15, to describe Infliximab and Biosimilar sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Infliximab and Biosimilar
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Infliximab and Biosimilar Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Infliximab
1.3.3 Infliximab-dyyb
1.3.4 Infliximab-abda
1.4 Market Analysis by Application
1.4.1 Overview: Global Infliximab and Biosimilar Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Crohn's Disease
1.4.3 Pediatric Crohn's Disease
1.4.4 Ulcerative Colitis
1.4.5 Rheumatoid Arthritis
1.4.6 Ankylosing Spondylitis
1.4.7 Psoriatic Arthritis
1.4.8 Plaque Psoriasis
1.5 Global Infliximab and Biosimilar Market Size & Forecast
1.5.1 Global Infliximab and Biosimilar Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Infliximab and Biosimilar Sales Quantity (2019-2030)
1.5.3 Global Infliximab and Biosimilar Average Price (2019-2030)
2 MANUFACTURERS PROFILES
2.1 Janssen Biotech
2.1.1 Janssen Biotech Details
2.1.2 Janssen Biotech Major Business
2.1.3 Janssen Biotech Infliximab and Biosimilar Product and Services
2.1.4 Janssen Biotech Infliximab and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Janssen Biotech Recent Developments/Updates
2.2 Merck and Co.
2.2.1 Merck and Co. Details
2.2.2 Merck and Co. Major Business
2.2.3 Merck and Co. Infliximab and Biosimilar Product and Services
2.2.4 Merck and Co. Infliximab and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Merck and Co. Recent Developments/Updates
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business
2.3.3 Pfizer Infliximab and Biosimilar Product and Services
2.3.4 Pfizer Infliximab and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Pfizer Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: INFLIXIMAB AND BIOSIMILAR BY MANUFACTURER
3.1 Global Infliximab and Biosimilar Sales Quantity by Manufacturer (2019-2024)
3.2 Global Infliximab and Biosimilar Revenue by Manufacturer (2019-2024)
3.3 Global Infliximab and Biosimilar Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of Infliximab and Biosimilar by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 Infliximab and Biosimilar Manufacturer Market Share in 2023
3.4.2 Top 6 Infliximab and Biosimilar Manufacturer Market Share in 2023
3.5 Infliximab and Biosimilar Market: Overall Company Footprint Analysis
3.5.1 Infliximab and Biosimilar Market: Region Footprint
3.5.2 Infliximab and Biosimilar Market: Company Product Type Footprint
3.5.3 Infliximab and Biosimilar Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Infliximab and Biosimilar Market Size by Region
4.1.1 Global Infliximab and Biosimilar Sales Quantity by Region (2019-2030)
4.1.2 Global Infliximab and Biosimilar Consumption Value by Region (2019-2030)
4.1.3 Global Infliximab and Biosimilar Average Price by Region (2019-2030)
4.2 North America Infliximab and Biosimilar Consumption Value (2019-2030)
4.3 Europe Infliximab and Biosimilar Consumption Value (2019-2030)
4.4 Asia-Pacific Infliximab and Biosimilar Consumption Value (2019-2030)
4.5 South America Infliximab and Biosimilar Consumption Value (2019-2030)
4.6 Middle East and Africa Infliximab and Biosimilar Consumption Value (2019-2030)
5 MARKET SEGMENT BY TYPE
5.1 Global Infliximab and Biosimilar Sales Quantity by Type (2019-2030)
5.2 Global Infliximab and Biosimilar Consumption Value by Type (2019-2030)
5.3 Global Infliximab and Biosimilar Average Price by Type (2019-2030)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Infliximab and Biosimilar Sales Quantity by Application (2019-2030)
6.2 Global Infliximab and Biosimilar Consumption Value by Application (2019-2030)
6.3 Global Infliximab and Biosimilar Average Price by Application (2019-2030)
7 NORTH AMERICA
7.1 North America Infliximab and Biosimilar Sales Quantity by Type (2019-2030)
7.2 North America Infliximab and Biosimilar Sales Quantity by Application (2019-2030)
7.3 North America Infliximab and Biosimilar Market Size by Country
7.3.1 North America Infliximab and Biosimilar Sales Quantity by Country (2019-2030)
7.3.2 North America Infliximab and Biosimilar Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8 EUROPE
8.1 Europe Infliximab and Biosimilar Sales Quantity by Type (2019-2030)
8.2 Europe Infliximab and Biosimilar Sales Quantity by Application (2019-2030)
8.3 Europe Infliximab and Biosimilar Market Size by Country
8.3.1 Europe Infliximab and Biosimilar Sales Quantity by Country (2019-2030)
8.3.2 Europe Infliximab and Biosimilar Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9 ASIA-PACIFIC
9.1 Asia-Pacific Infliximab and Biosimilar Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Infliximab and Biosimilar Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Infliximab and Biosimilar Market Size by Region
9.3.1 Asia-Pacific Infliximab and Biosimilar Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Infliximab and Biosimilar Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10 SOUTH AMERICA
10.1 South America Infliximab and Biosimilar Sales Quantity by Type (2019-2030)
10.2 South America Infliximab and Biosimilar Sales Quantity by Application (2019-2030)
10.3 South America Infliximab and Biosimilar Market Size by Country
10.3.1 South America Infliximab and Biosimilar Sales Quantity by Country (2019-2030)
10.3.2 South America Infliximab and Biosimilar Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Infliximab and Biosimilar Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Infliximab and Biosimilar Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Infliximab and Biosimilar Market Size by Country
11.3.1 Middle East & Africa Infliximab and Biosimilar Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Infliximab and Biosimilar Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12 MARKET DYNAMICS
12.1 Infliximab and Biosimilar Market Drivers
12.2 Infliximab and Biosimilar Market Restraints
12.3 Infliximab and Biosimilar Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Infliximab and Biosimilar and Key Manufacturers
13.2 Manufacturing Costs Percentage of Infliximab and Biosimilar
13.3 Infliximab and Biosimilar Production Process
13.4 Infliximab and Biosimilar Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Infliximab and Biosimilar Typical Distributors
14.3 Infliximab and Biosimilar Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Infliximab and Biosimilar Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Infliximab and Biosimilar Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Janssen Biotech Basic Information, Manufacturing Base and Competitors
Table 4. Janssen Biotech Major Business
Table 5. Janssen Biotech Infliximab and Biosimilar Product and Services
Table 6. Janssen Biotech Infliximab and Biosimilar Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Janssen Biotech Recent Developments/Updates
Table 8. Merck and Co. Basic Information, Manufacturing Base and Competitors
Table 9. Merck and Co. Major Business
Table 10. Merck and Co. Infliximab and Biosimilar Product and Services
Table 11. Merck and Co. Infliximab and Biosimilar Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. Merck and Co. Recent Developments/Updates
Table 13. Pfizer Basic Information, Manufacturing Base and Competitors
Table 14. Pfizer Major Business
Table 15. Pfizer Infliximab and Biosimilar Product and Services
Table 16. Pfizer Infliximab and Biosimilar Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. Pfizer Recent Developments/Updates
Table 18. Global Infliximab and Biosimilar Sales Quantity by Manufacturer (2019-2024) & (K Units)
Table 19. Global Infliximab and Biosimilar Revenue by Manufacturer (2019-2024) & (USD Million)
Table 20. Global Infliximab and Biosimilar Average Price by Manufacturer (2019-2024) & (USD/Unit)
Table 21. Market Position of Manufacturers in Infliximab and Biosimilar, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
Table 22. Head Office and Infliximab and Biosimilar Production Site of Key Manufacturer
Table 23. Infliximab and Biosimilar Market: Company Product Type Footprint
Table 24. Infliximab and Biosimilar Market: Company Product Application Footprint
Table 25. Infliximab and Biosimilar New Market Entrants and Barriers to Market Entry
Table 26. Infliximab and Biosimilar Mergers, Acquisition, Agreements, and Collaborations
Table 27. Global Infliximab and Biosimilar Sales Quantity by Region (2019-2024) & (K Units)
Table 28. Global Infliximab and Biosimilar Sales Quantity by Region (2025-2030) & (K Units)
Table 29. Global Infliximab and Biosimilar Consumption Value by Region (2019-2024) & (USD Million)
Table 30. Global Infliximab and Biosimilar Consumption Value by Region (2025-2030) & (USD Million)
Table 31. Global Infliximab and Biosimilar Average Price by Region (2019-2024) & (USD/Unit)
Table 32. Global Infliximab and Biosimilar Average Price by Region (2025-2030) & (USD/Unit)
Table 33. Global Infliximab and Biosimilar Sales Quantity by Type (2019-2024) & (K Units)
Table 34. Global Infliximab and Biosimilar Sales Quantity by Type (2025-2030) & (K Units)
Table 35. Global Infliximab and Biosimilar Consumption Value by Type (2019-2024) & (USD Million)
Table 36. Global Infliximab and Biosimilar Consumption Value by Type (2025-2030) & (USD Million)
Table 37. Global Infliximab and Biosimilar Average Price by Type (2019-2024) & (USD/Unit)
Table 38. Global Infliximab and Biosimilar Average Price by Type (2025-2030) & (USD/Unit)
Table 39. Global Infliximab and Biosimilar Sales Quantity by Application (2019-2024) & (K Units)
Table 40. Global Infliximab and Biosimilar Sales Quantity by Application (2025-2030) & (K Units)
Table 41. Global Infliximab and Biosimilar Consumption Value by Application (2019-2024) & (USD Million)
Table 42. Global Infliximab and Biosimilar Consumption Value by Application (2025-2030) & (USD Million)
Table 43. Global Infliximab and Biosimilar Average Price by Application (2019-2024) & (USD/Unit)
Table 44. Global Infliximab and Biosimilar Average Price by Application (2025-2030) & (USD/Unit)
Table 45. North America Infliximab and Biosimilar Sales Quantity by Type (2019-2024) & (K Units)
Table 46. North America Infliximab and Biosimilar Sales Quantity by Type (2025-2030) & (K Units)
Table 47. North America Infliximab and Biosimilar Sales Quantity by Application (2019-2024) & (K Units)
Table 48. North America Infliximab and Biosimilar Sales Quantity by Application (2025-2030) & (K Units)
Table 49. North America Infliximab and Biosimilar Sales Quantity by Country (2019-2024) & (K Units)
Table 50. North America Infliximab and Biosimilar Sales Quantity by Country (2025-2030) & (K Units)
Table 51. North America Infliximab and Biosimilar Consumption Value by Country (2019-2024) & (USD Million)
Table 52. North America Infliximab and Biosimilar Consumption Value by Country (2025-2030) & (USD Million)
Table 53. Europe Infliximab and Biosimilar Sales Quantity by Type (2019-2024) & (K Units)
Table 54. Europe Infliximab and Biosimilar Sales Quantity by Type (2025-2030) & (K Units)
Table 55. Europe Infliximab and Biosimilar Sales Quantity by Application (2019-2024) & (K Units)
Table 56. Europe Infliximab and Biosimilar Sales Quantity by Application (2025-2030) & (K Units)
Table 57. Europe Infliximab and Biosimilar Sales Quantity by Country (2019-2024) & (K Units)
Table 58. Europe Infliximab and Biosimilar Sales Quantity by Country (2025-2030) & (K Units)
Table 59. Europe Infliximab and Biosimilar Consumption Value by Country (2019-2024) & (USD Million)
Table 60. Europe Infliximab and Biosimilar Consumption Value by Country (2025-2030) & (USD Million)
Table 61. Asia-Pacific Infliximab and Biosimilar Sales Quantity by Type (2019-2024) & (K Units)
Table 62. Asia-Pacific Infliximab and Biosimilar Sales Quantity by Type (2025-2030) & (K Units)
Table 63. Asia-Pacific Infliximab and Biosimilar Sales Quantity by Application (2019-2024) & (K Units)
Table 64. Asia-Pacific Infliximab and Biosimilar Sales Quantity by Application (2025-2030) & (K Units)
Table 65. Asia-Pacific Infliximab and Biosimilar Sales Quantity by Region (2019-2024) & (K Units)
Table 66. Asia-Pacific Infliximab and Biosimilar Sales Quantity by Region (2025-2030) & (K Units)
Table 67. Asia-Pacific Infliximab and Biosimilar Consumption Value by Region (2019-2024) & (USD Million)
Table 68. Asia-Pacific Infliximab and Biosimilar Consumption Value by Region (2025-2030) & (USD Million)
Table 69. South America Infliximab and Biosimilar Sales Quantity by Type (2019-2024) & (K Units)
Table 70. South America Infliximab and Biosimilar Sales Quantity by Type (2025-2030) & (K Units)
Table 71. South America Infliximab and Biosimilar Sales Quantity by Application (2019-2024) & (K Units)
Table 72. South America Infliximab and Biosimilar Sales Quantity by Application (2025-2030) & (K Units)
Table 73. South America Infliximab and Biosimilar Sales Quantity by Country (2019-2024) & (K Units)
Table 74. South America Infliximab and Biosimilar Sales Quantity by Country (2025-2030) & (K Units)
Table 75. South America Infliximab and Biosimilar Consumption Value by Country (2019-2024) & (USD Million)
Table 76. South America Infliximab and Biosimilar Consumption Value by Country (2025-2030) & (USD Million)
Table 77. Middle East & Africa Infliximab and Biosimilar Sales Quantity by Type (2019-2024) & (K Units)
Table 78. Middle East & Africa Infliximab and Biosimilar Sales Quantity by Type (2025-2030) & (K Units)
Table 79. Middle East & Africa Infliximab and Biosimilar Sales Quantity by Application (2019-2024) & (K Units)
Table 80. Middle East & Africa Infliximab and Biosimilar Sales Quantity by Application (2025-2030) & (K Units)
Table 81. Middle East & Africa Infliximab and Biosimilar Sales Quantity by Region (2019-2024) & (K Units)
Table 82. Middle East & Africa Infliximab and Biosimilar Sales Quantity by Region (2025-2030) & (K Units)
Table 83. Middle East & Africa Infliximab and Biosimilar Consumption Value by Region (2019-2024) & (USD Million)
Table 84. Middle East & Africa Infliximab and Biosimilar Consumption Value by Region (2025-2030) & (USD Million)
Table 85. Infliximab and Biosimilar Raw Material
Table 86. Key Manufacturers of Infliximab and Biosimilar Raw Materials
Table 87. Infliximab and Biosimilar Typical Distributors
Table 88. Infliximab and Biosimilar Typical Customers
Table 1. Global Infliximab and Biosimilar Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Infliximab and Biosimilar Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Janssen Biotech Basic Information, Manufacturing Base and Competitors
Table 4. Janssen Biotech Major Business
Table 5. Janssen Biotech Infliximab and Biosimilar Product and Services
Table 6. Janssen Biotech Infliximab and Biosimilar Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Janssen Biotech Recent Developments/Updates
Table 8. Merck and Co. Basic Information, Manufacturing Base and Competitors
Table 9. Merck and Co. Major Business
Table 10. Merck and Co. Infliximab and Biosimilar Product and Services
Table 11. Merck and Co. Infliximab and Biosimilar Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. Merck and Co. Recent Developments/Updates
Table 13. Pfizer Basic Information, Manufacturing Base and Competitors
Table 14. Pfizer Major Business
Table 15. Pfizer Infliximab and Biosimilar Product and Services
Table 16. Pfizer Infliximab and Biosimilar Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. Pfizer Recent Developments/Updates
Table 18. Global Infliximab and Biosimilar Sales Quantity by Manufacturer (2019-2024) & (K Units)
Table 19. Global Infliximab and Biosimilar Revenue by Manufacturer (2019-2024) & (USD Million)
Table 20. Global Infliximab and Biosimilar Average Price by Manufacturer (2019-2024) & (USD/Unit)
Table 21. Market Position of Manufacturers in Infliximab and Biosimilar, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
Table 22. Head Office and Infliximab and Biosimilar Production Site of Key Manufacturer
Table 23. Infliximab and Biosimilar Market: Company Product Type Footprint
Table 24. Infliximab and Biosimilar Market: Company Product Application Footprint
Table 25. Infliximab and Biosimilar New Market Entrants and Barriers to Market Entry
Table 26. Infliximab and Biosimilar Mergers, Acquisition, Agreements, and Collaborations
Table 27. Global Infliximab and Biosimilar Sales Quantity by Region (2019-2024) & (K Units)
Table 28. Global Infliximab and Biosimilar Sales Quantity by Region (2025-2030) & (K Units)
Table 29. Global Infliximab and Biosimilar Consumption Value by Region (2019-2024) & (USD Million)
Table 30. Global Infliximab and Biosimilar Consumption Value by Region (2025-2030) & (USD Million)
Table 31. Global Infliximab and Biosimilar Average Price by Region (2019-2024) & (USD/Unit)
Table 32. Global Infliximab and Biosimilar Average Price by Region (2025-2030) & (USD/Unit)
Table 33. Global Infliximab and Biosimilar Sales Quantity by Type (2019-2024) & (K Units)
Table 34. Global Infliximab and Biosimilar Sales Quantity by Type (2025-2030) & (K Units)
Table 35. Global Infliximab and Biosimilar Consumption Value by Type (2019-2024) & (USD Million)
Table 36. Global Infliximab and Biosimilar Consumption Value by Type (2025-2030) & (USD Million)
Table 37. Global Infliximab and Biosimilar Average Price by Type (2019-2024) & (USD/Unit)
Table 38. Global Infliximab and Biosimilar Average Price by Type (2025-2030) & (USD/Unit)
Table 39. Global Infliximab and Biosimilar Sales Quantity by Application (2019-2024) & (K Units)
Table 40. Global Infliximab and Biosimilar Sales Quantity by Application (2025-2030) & (K Units)
Table 41. Global Infliximab and Biosimilar Consumption Value by Application (2019-2024) & (USD Million)
Table 42. Global Infliximab and Biosimilar Consumption Value by Application (2025-2030) & (USD Million)
Table 43. Global Infliximab and Biosimilar Average Price by Application (2019-2024) & (USD/Unit)
Table 44. Global Infliximab and Biosimilar Average Price by Application (2025-2030) & (USD/Unit)
Table 45. North America Infliximab and Biosimilar Sales Quantity by Type (2019-2024) & (K Units)
Table 46. North America Infliximab and Biosimilar Sales Quantity by Type (2025-2030) & (K Units)
Table 47. North America Infliximab and Biosimilar Sales Quantity by Application (2019-2024) & (K Units)
Table 48. North America Infliximab and Biosimilar Sales Quantity by Application (2025-2030) & (K Units)
Table 49. North America Infliximab and Biosimilar Sales Quantity by Country (2019-2024) & (K Units)
Table 50. North America Infliximab and Biosimilar Sales Quantity by Country (2025-2030) & (K Units)
Table 51. North America Infliximab and Biosimilar Consumption Value by Country (2019-2024) & (USD Million)
Table 52. North America Infliximab and Biosimilar Consumption Value by Country (2025-2030) & (USD Million)
Table 53. Europe Infliximab and Biosimilar Sales Quantity by Type (2019-2024) & (K Units)
Table 54. Europe Infliximab and Biosimilar Sales Quantity by Type (2025-2030) & (K Units)
Table 55. Europe Infliximab and Biosimilar Sales Quantity by Application (2019-2024) & (K Units)
Table 56. Europe Infliximab and Biosimilar Sales Quantity by Application (2025-2030) & (K Units)
Table 57. Europe Infliximab and Biosimilar Sales Quantity by Country (2019-2024) & (K Units)
Table 58. Europe Infliximab and Biosimilar Sales Quantity by Country (2025-2030) & (K Units)
Table 59. Europe Infliximab and Biosimilar Consumption Value by Country (2019-2024) & (USD Million)
Table 60. Europe Infliximab and Biosimilar Consumption Value by Country (2025-2030) & (USD Million)
Table 61. Asia-Pacific Infliximab and Biosimilar Sales Quantity by Type (2019-2024) & (K Units)
Table 62. Asia-Pacific Infliximab and Biosimilar Sales Quantity by Type (2025-2030) & (K Units)
Table 63. Asia-Pacific Infliximab and Biosimilar Sales Quantity by Application (2019-2024) & (K Units)
Table 64. Asia-Pacific Infliximab and Biosimilar Sales Quantity by Application (2025-2030) & (K Units)
Table 65. Asia-Pacific Infliximab and Biosimilar Sales Quantity by Region (2019-2024) & (K Units)
Table 66. Asia-Pacific Infliximab and Biosimilar Sales Quantity by Region (2025-2030) & (K Units)
Table 67. Asia-Pacific Infliximab and Biosimilar Consumption Value by Region (2019-2024) & (USD Million)
Table 68. Asia-Pacific Infliximab and Biosimilar Consumption Value by Region (2025-2030) & (USD Million)
Table 69. South America Infliximab and Biosimilar Sales Quantity by Type (2019-2024) & (K Units)
Table 70. South America Infliximab and Biosimilar Sales Quantity by Type (2025-2030) & (K Units)
Table 71. South America Infliximab and Biosimilar Sales Quantity by Application (2019-2024) & (K Units)
Table 72. South America Infliximab and Biosimilar Sales Quantity by Application (2025-2030) & (K Units)
Table 73. South America Infliximab and Biosimilar Sales Quantity by Country (2019-2024) & (K Units)
Table 74. South America Infliximab and Biosimilar Sales Quantity by Country (2025-2030) & (K Units)
Table 75. South America Infliximab and Biosimilar Consumption Value by Country (2019-2024) & (USD Million)
Table 76. South America Infliximab and Biosimilar Consumption Value by Country (2025-2030) & (USD Million)
Table 77. Middle East & Africa Infliximab and Biosimilar Sales Quantity by Type (2019-2024) & (K Units)
Table 78. Middle East & Africa Infliximab and Biosimilar Sales Quantity by Type (2025-2030) & (K Units)
Table 79. Middle East & Africa Infliximab and Biosimilar Sales Quantity by Application (2019-2024) & (K Units)
Table 80. Middle East & Africa Infliximab and Biosimilar Sales Quantity by Application (2025-2030) & (K Units)
Table 81. Middle East & Africa Infliximab and Biosimilar Sales Quantity by Region (2019-2024) & (K Units)
Table 82. Middle East & Africa Infliximab and Biosimilar Sales Quantity by Region (2025-2030) & (K Units)
Table 83. Middle East & Africa Infliximab and Biosimilar Consumption Value by Region (2019-2024) & (USD Million)
Table 84. Middle East & Africa Infliximab and Biosimilar Consumption Value by Region (2025-2030) & (USD Million)
Table 85. Infliximab and Biosimilar Raw Material
Table 86. Key Manufacturers of Infliximab and Biosimilar Raw Materials
Table 87. Infliximab and Biosimilar Typical Distributors
Table 88. Infliximab and Biosimilar Typical Customers
LIST OF FIGURES
Figure 1. Infliximab and Biosimilar Picture
Figure 2. Global Infliximab and Biosimilar Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Infliximab and Biosimilar Consumption Value Market Share by Type in 2023
Figure 4. Infliximab Examples
Figure 5. Infliximab-dyyb Examples
Figure 6. Infliximab-abda Examples
Figure 7. Global Infliximab and Biosimilar Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 8. Global Infliximab and Biosimilar Consumption Value Market Share by Application in 2023
Figure 9. Crohn's Disease Examples
Figure 10. Pediatric Crohn's Disease Examples
Figure 11. Ulcerative Colitis Examples
Figure 12. Rheumatoid Arthritis Examples
Figure 13. Ankylosing Spondylitis Examples
Figure 14. Psoriatic Arthritis Examples
Figure 15. Plaque Psoriasis Examples
Figure 16. Global Infliximab and Biosimilar Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 17. Global Infliximab and Biosimilar Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 18. Global Infliximab and Biosimilar Sales Quantity (2019-2030) & (K Units)
Figure 19. Global Infliximab and Biosimilar Average Price (2019-2030) & (USD/Unit)
Figure 20. Global Infliximab and Biosimilar Sales Quantity Market Share by Manufacturer in 2023
Figure 21. Global Infliximab and Biosimilar Consumption Value Market Share by Manufacturer in 2023
Figure 22. Producer Shipments of Infliximab and Biosimilar by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
Figure 23. Top 3 Infliximab and Biosimilar Manufacturer (Consumption Value) Market Share in 2023
Figure 24. Top 6 Infliximab and Biosimilar Manufacturer (Consumption Value) Market Share in 2023
Figure 25. Global Infliximab and Biosimilar Sales Quantity Market Share by Region (2019-2030)
Figure 26. Global Infliximab and Biosimilar Consumption Value Market Share by Region (2019-2030)
Figure 27. North America Infliximab and Biosimilar Consumption Value (2019-2030) & (USD Million)
Figure 28. Europe Infliximab and Biosimilar Consumption Value (2019-2030) & (USD Million)
Figure 29. Asia-Pacific Infliximab and Biosimilar Consumption Value (2019-2030) & (USD Million)
Figure 30. South America Infliximab and Biosimilar Consumption Value (2019-2030) & (USD Million)
Figure 31. Middle East & Africa Infliximab and Biosimilar Consumption Value (2019-2030) & (USD Million)
Figure 32. Global Infliximab and Biosimilar Sales Quantity Market Share by Type (2019-2030)
Figure 33. Global Infliximab and Biosimilar Consumption Value Market Share by Type (2019-2030)
Figure 34. Global Infliximab and Biosimilar Average Price by Type (2019-2030) & (USD/Unit)
Figure 35. Global Infliximab and Biosimilar Sales Quantity Market Share by Application (2019-2030)
Figure 36. Global Infliximab and Biosimilar Consumption Value Market Share by Application (2019-2030)
Figure 37. Global Infliximab and Biosimilar Average Price by Application (2019-2030) & (USD/Unit)
Figure 38. North America Infliximab and Biosimilar Sales Quantity Market Share by Type (2019-2030)
Figure 39. North America Infliximab and Biosimilar Sales Quantity Market Share by Application (2019-2030)
Figure 40. North America Infliximab and Biosimilar Sales Quantity Market Share by Country (2019-2030)
Figure 41. North America Infliximab and Biosimilar Consumption Value Market Share by Country (2019-2030)
Figure 42. United States Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 43. Canada Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 44. Mexico Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 45. Europe Infliximab and Biosimilar Sales Quantity Market Share by Type (2019-2030)
Figure 46. Europe Infliximab and Biosimilar Sales Quantity Market Share by Application (2019-2030)
Figure 47. Europe Infliximab and Biosimilar Sales Quantity Market Share by Country (2019-2030)
Figure 48. Europe Infliximab and Biosimilar Consumption Value Market Share by Country (2019-2030)
Figure 49. Germany Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 50. France Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 51. United Kingdom Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 52. Russia Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 53. Italy Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 54. Asia-Pacific Infliximab and Biosimilar Sales Quantity Market Share by Type (2019-2030)
Figure 55. Asia-Pacific Infliximab and Biosimilar Sales Quantity Market Share by Application (2019-2030)
Figure 56. Asia-Pacific Infliximab and Biosimilar Sales Quantity Market Share by Region (2019-2030)
Figure 57. Asia-Pacific Infliximab and Biosimilar Consumption Value Market Share by Region (2019-2030)
Figure 58. China Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 59. Japan Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 60. Korea Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 61. India Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 62. Southeast Asia Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 63. Australia Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 64. South America Infliximab and Biosimilar Sales Quantity Market Share by Type (2019-2030)
Figure 65. South America Infliximab and Biosimilar Sales Quantity Market Share by Application (2019-2030)
Figure 66. South America Infliximab and Biosimilar Sales Quantity Market Share by Country (2019-2030)
Figure 67. South America Infliximab and Biosimilar Consumption Value Market Share by Country (2019-2030)
Figure 68. Brazil Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 69. Argentina Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 70. Middle East & Africa Infliximab and Biosimilar Sales Quantity Market Share by Type (2019-2030)
Figure 71. Middle East & Africa Infliximab and Biosimilar Sales Quantity Market Share by Application (2019-2030)
Figure 72. Middle East & Africa Infliximab and Biosimilar Sales Quantity Market Share by Region (2019-2030)
Figure 73. Middle East & Africa Infliximab and Biosimilar Consumption Value Market Share by Region (2019-2030)
Figure 74. Turkey Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 75. Egypt Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 76. Saudi Arabia Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 77. South Africa Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 78. Infliximab and Biosimilar Market Drivers
Figure 79. Infliximab and Biosimilar Market Restraints
Figure 80. Infliximab and Biosimilar Market Trends
Figure 81. Porters Five Forces Analysis
Figure 82. Manufacturing Cost Structure Analysis of Infliximab and Biosimilar in 2023
Figure 83. Manufacturing Process Analysis of Infliximab and Biosimilar
Figure 84. Infliximab and Biosimilar Industrial Chain
Figure 85. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 86. Direct Channel Pros & Cons
Figure 87. Indirect Channel Pros & Cons
Figure 88. Methodology
Figure 89. Research Process and Data Source
Figure 1. Infliximab and Biosimilar Picture
Figure 2. Global Infliximab and Biosimilar Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Infliximab and Biosimilar Consumption Value Market Share by Type in 2023
Figure 4. Infliximab Examples
Figure 5. Infliximab-dyyb Examples
Figure 6. Infliximab-abda Examples
Figure 7. Global Infliximab and Biosimilar Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 8. Global Infliximab and Biosimilar Consumption Value Market Share by Application in 2023
Figure 9. Crohn's Disease Examples
Figure 10. Pediatric Crohn's Disease Examples
Figure 11. Ulcerative Colitis Examples
Figure 12. Rheumatoid Arthritis Examples
Figure 13. Ankylosing Spondylitis Examples
Figure 14. Psoriatic Arthritis Examples
Figure 15. Plaque Psoriasis Examples
Figure 16. Global Infliximab and Biosimilar Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 17. Global Infliximab and Biosimilar Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 18. Global Infliximab and Biosimilar Sales Quantity (2019-2030) & (K Units)
Figure 19. Global Infliximab and Biosimilar Average Price (2019-2030) & (USD/Unit)
Figure 20. Global Infliximab and Biosimilar Sales Quantity Market Share by Manufacturer in 2023
Figure 21. Global Infliximab and Biosimilar Consumption Value Market Share by Manufacturer in 2023
Figure 22. Producer Shipments of Infliximab and Biosimilar by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
Figure 23. Top 3 Infliximab and Biosimilar Manufacturer (Consumption Value) Market Share in 2023
Figure 24. Top 6 Infliximab and Biosimilar Manufacturer (Consumption Value) Market Share in 2023
Figure 25. Global Infliximab and Biosimilar Sales Quantity Market Share by Region (2019-2030)
Figure 26. Global Infliximab and Biosimilar Consumption Value Market Share by Region (2019-2030)
Figure 27. North America Infliximab and Biosimilar Consumption Value (2019-2030) & (USD Million)
Figure 28. Europe Infliximab and Biosimilar Consumption Value (2019-2030) & (USD Million)
Figure 29. Asia-Pacific Infliximab and Biosimilar Consumption Value (2019-2030) & (USD Million)
Figure 30. South America Infliximab and Biosimilar Consumption Value (2019-2030) & (USD Million)
Figure 31. Middle East & Africa Infliximab and Biosimilar Consumption Value (2019-2030) & (USD Million)
Figure 32. Global Infliximab and Biosimilar Sales Quantity Market Share by Type (2019-2030)
Figure 33. Global Infliximab and Biosimilar Consumption Value Market Share by Type (2019-2030)
Figure 34. Global Infliximab and Biosimilar Average Price by Type (2019-2030) & (USD/Unit)
Figure 35. Global Infliximab and Biosimilar Sales Quantity Market Share by Application (2019-2030)
Figure 36. Global Infliximab and Biosimilar Consumption Value Market Share by Application (2019-2030)
Figure 37. Global Infliximab and Biosimilar Average Price by Application (2019-2030) & (USD/Unit)
Figure 38. North America Infliximab and Biosimilar Sales Quantity Market Share by Type (2019-2030)
Figure 39. North America Infliximab and Biosimilar Sales Quantity Market Share by Application (2019-2030)
Figure 40. North America Infliximab and Biosimilar Sales Quantity Market Share by Country (2019-2030)
Figure 41. North America Infliximab and Biosimilar Consumption Value Market Share by Country (2019-2030)
Figure 42. United States Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 43. Canada Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 44. Mexico Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 45. Europe Infliximab and Biosimilar Sales Quantity Market Share by Type (2019-2030)
Figure 46. Europe Infliximab and Biosimilar Sales Quantity Market Share by Application (2019-2030)
Figure 47. Europe Infliximab and Biosimilar Sales Quantity Market Share by Country (2019-2030)
Figure 48. Europe Infliximab and Biosimilar Consumption Value Market Share by Country (2019-2030)
Figure 49. Germany Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 50. France Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 51. United Kingdom Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 52. Russia Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 53. Italy Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 54. Asia-Pacific Infliximab and Biosimilar Sales Quantity Market Share by Type (2019-2030)
Figure 55. Asia-Pacific Infliximab and Biosimilar Sales Quantity Market Share by Application (2019-2030)
Figure 56. Asia-Pacific Infliximab and Biosimilar Sales Quantity Market Share by Region (2019-2030)
Figure 57. Asia-Pacific Infliximab and Biosimilar Consumption Value Market Share by Region (2019-2030)
Figure 58. China Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 59. Japan Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 60. Korea Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 61. India Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 62. Southeast Asia Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 63. Australia Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 64. South America Infliximab and Biosimilar Sales Quantity Market Share by Type (2019-2030)
Figure 65. South America Infliximab and Biosimilar Sales Quantity Market Share by Application (2019-2030)
Figure 66. South America Infliximab and Biosimilar Sales Quantity Market Share by Country (2019-2030)
Figure 67. South America Infliximab and Biosimilar Consumption Value Market Share by Country (2019-2030)
Figure 68. Brazil Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 69. Argentina Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 70. Middle East & Africa Infliximab and Biosimilar Sales Quantity Market Share by Type (2019-2030)
Figure 71. Middle East & Africa Infliximab and Biosimilar Sales Quantity Market Share by Application (2019-2030)
Figure 72. Middle East & Africa Infliximab and Biosimilar Sales Quantity Market Share by Region (2019-2030)
Figure 73. Middle East & Africa Infliximab and Biosimilar Consumption Value Market Share by Region (2019-2030)
Figure 74. Turkey Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 75. Egypt Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 76. Saudi Arabia Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 77. South Africa Infliximab and Biosimilar Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 78. Infliximab and Biosimilar Market Drivers
Figure 79. Infliximab and Biosimilar Market Restraints
Figure 80. Infliximab and Biosimilar Market Trends
Figure 81. Porters Five Forces Analysis
Figure 82. Manufacturing Cost Structure Analysis of Infliximab and Biosimilar in 2023
Figure 83. Manufacturing Process Analysis of Infliximab and Biosimilar
Figure 84. Infliximab and Biosimilar Industrial Chain
Figure 85. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 86. Direct Channel Pros & Cons
Figure 87. Indirect Channel Pros & Cons
Figure 88. Methodology
Figure 89. Research Process and Data Source
